Thyrocare Technologies Limited Just Missed EPS By 73%: Here's What Analysts Think Will Happen Next
As you might know, Thyrocare Technologies Limited (NSE:THYROCARE) recently reported its quarterly numbers. Revenue of ₹2.7b surpassed estimates by 2.3%, although statutory earnings per share missed badly, coming in 73% below expectations at ₹0.95 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following the latest results, Thyrocare Technologies' five analysts are now forecasting revenues of ₹10.1b in 2027. This would be a decent 8.3% improvement in revenue compared to the last 12 months. Per-share earnings are expected to shoot up 47% to ₹13.30. In the lead-up to this report, the analysts had been modelling revenues of ₹9.97b and earnings per share (EPS) of ₹13.13 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
View our latest analysis for Thyrocare Technologies
The analysts reconfirmed their price target of ₹681, showing that the business is executing well and in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Thyrocare Technologies, with the most bullish analyst valuing it at ₹729 and the most bearish at ₹614 per share. This is a very narrow spread of estimates, implying either that Thyrocare Technologies is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Thyrocare Technologies' growth to accelerate, with the forecast 17% annualised growth to the end of 2027 ranking favourably alongside historical growth of 10% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 19% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Thyrocare Technologies is expected to grow at about the same rate as the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Thyrocare Technologies analysts - going out to 2029, and you can see them free on our platform here.
You still need to take note of risks, for example - Thyrocare Technologies has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.